|
Market Closed -
Sao Paulo
01:39:00 19/09/2026 am IST
|
5-day change | 1st Jan Change | ||
| 75.00 BRL | -7.06% |
|
+8.38% | +13.71% |
| 16/09 | Sling Therapeutics raises $123 million to advance thyroid eye disease drug | RE |
| 15/09 | Amgen Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM |
| Market Cap | 21TCr 1,07700Cr 18TCr 17TCr 16TCr 29TCr 20,00600Cr 29TCr 2,05600Cr 79TCr 10,17100Cr 78TCr 77TCr 32,72800Cr | P/E 2026 * |
24.4x | P/E 2027 * | 21.9x |
|---|---|---|---|---|---|
| Enterprise Value | 25TCr 1,29100Cr 22TCr 21TCr 19TCr 35TCr 23,98700Cr 35TCr 2,46500Cr 95TCr 12,19500Cr 94TCr 92TCr 39,24000Cr | EV / Sales 2026 * |
6.42x | EV / Sales 2027 * | 6.07x |
| Free-Float |
99.77% | Yield 2026 * |
2.62% | Yield 2027 * | 2.76% |
Last Transcript: Amgen Inc.
| 1 day | -7.06% | ||
| 1 week | +8.38% | ||
| Current month | -5.96% | ||
| 1 month | -5.18% | ||
| 3 months | +20.40% | ||
| 6 months | +14.54% | ||
| Current year | +13.71% |
| 1 week | 68.98 |  | 80.47 |
| 1 month | 68.98 | | 82.26 |
| Current year | 48.4 | | 83.38 |
| 1 year | 48.4 | | 83.38 |
| 3 years | 45.12 | | 83.38 |
| 5 years | 37.52 | | 83.38 |
| 10 years | 15.78 | | 83.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
| Director of Finance/CFO | 62 | 13/05/2010 | |
Paul Burton
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/06/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -7.06% | +8.38% | - | - | 21TCr | |
| +0.04% | +3.34% | +51.12% | +101.82% | 1,02800Cr | |
| -0.09% | +1.66% | +55.02% | +66.18% | 65TCr | |
| -0.02% | +2.66% | +18.91% | +71.47% | 47TCr | |
| -1.22% | +3.66% | +36.44% | +38.32% | 35TCr | |
| -0.79% | +2.73% | +19.03% | +25.08% | 27TCr | |
| +0.58% | +6.76% | +11.13% | +16.52% | 26TCr | |
| +1.55% | +2.20% | +39.81% | +46.55% | 21TCr | |
| +0.79% | +1.84% | -28.27% | -56.71% | 19TCr | |
| -0.52% | +4.45% | +32.12% | +98.51% | 19TCr | |
| Average | -0.52% | +3.26% | +26.15% | +45.30% | 40.02TCr | |
| Weighted average by Cap. | -0.17% | +3.09% | +35.15% | +61.76% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.89TCr 20TCr 3.4TCr 3.21TCr 2.91TCr 5.45TCr 3,73600Cr 5.48TCr 38TCr 15TCr 1,90000Cr 15TCr 14TCr 6,11200Cr | 4.02TCr 21TCr 3.51TCr 3.31TCr 3.01TCr 5.64TCr 3,86100Cr 5.66TCr 40TCr 15TCr 1,96300Cr 15TCr 15TCr 6,31500Cr |
| Net income | 867.84Cr 4.48TCr 756.75Cr 714.55Cr 648.86Cr 1.22TCr 83TCr 1.22TCr 8.56TCr 3.3TCr 42TCr 3.26TCr 3.19TCr 1,36200Cr | 934.18Cr 4.83TCr 814.6Cr 769.18Cr 698.47Cr 1.31TCr 90TCr 1.31TCr 9.21TCr 3.56TCr 46TCr 3.51TCr 3.43TCr 1,46600Cr |
| Net Debt | 4.15TCr 21TCr 3.62TCr 3.42TCr 3.1TCr 5.81TCr 3,98100Cr 5.84TCr 41TCr 16TCr 2,02400Cr 16TCr 15TCr 6,51200Cr | 3.58TCr 19TCr 3.12TCr 2.95TCr 2.68TCr 5.02TCr 3,43700Cr 5.04TCr 35TCr 14TCr 1,74700Cr 13TCr 13TCr 5,62200Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/26/18 | R$75.00 | +7.82% | 215 |
| 17/26/17 | R$69.56 | +0.49% | 359 |
| 16/26/16 | R$69.22 | -13.98% | 567 |
| 15/26/15 | R$80.47 | +14.63% | 368 |
| 14/26/14 | R$70.20 | +1.45% | 49 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AMGN Stock
- AMGN34 Stock
Select your edition
All financial news and data tailored to specific country editions
